96 related articles for article (PubMed ID: 7509751)
21. Selective antagonism of nigral neuropeptide responses to methamphetamine by conantokin G, a naturally occurring conopeptide.
Bush L; McCabe T; Hanson GR
Eur J Pharmacol; 2000 Jan; 387(1):55-8. PubMed ID: 10633160
[TBL] [Abstract][Full Text] [Related]
22. Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels.
Kogan FJ; Nichols WK; Gibb JW
Eur J Pharmacol; 1976 Apr; 36(2):363-71. PubMed ID: 6286
[TBL] [Abstract][Full Text] [Related]
23. Comparison of responses by neuropeptide systems in rat to the psychotropic drugs, methamphetamine, cocaine and PCP.
Hanson GR; Midgley LP; Bush LG; Johnson M; Gibb JW
NIDA Res Monogr; 1989; 95():348. PubMed ID: 2484267
[No Abstract] [Full Text] [Related]
24. Muscarinic antagonists in substantia nigra influence the decarboxylation of L-dopa in striatum.
Izurieta-Sánchez P; Sarre S; Ebinger G; Michotte Y
Eur J Pharmacol; 2000 Jul; 399(2-3):151-60. PubMed ID: 10884514
[TBL] [Abstract][Full Text] [Related]
25. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Biggs CS; Starr MS
Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
[TBL] [Abstract][Full Text] [Related]
26. Differential effects of antipsychotic and psychotomimetic drugs on neurotensin systems of discrete extrapyramidal and limbic regions.
Gygi SP; Gibb JW; Hanson GR
J Pharmacol Exp Ther; 1994 Jul; 270(1):192-7. PubMed ID: 7913495
[TBL] [Abstract][Full Text] [Related]
27. Epothilone D prevents binge methamphetamine-mediated loss of striatal dopaminergic markers.
Killinger BA; Moszczynska A
J Neurochem; 2016 Feb; 136(3):510-25. PubMed ID: 26465779
[TBL] [Abstract][Full Text] [Related]
28. Striatal glutamate release evoked in vivo by NMDA is dependent upon ongoing neuronal activity in the substantia nigra, endogenous striatal substance P and dopamine.
Marti M; Manzalini M; Fantin M; Bianchi C; Della Corte L; Morari M
J Neurochem; 2005 Apr; 93(1):195-205. PubMed ID: 15773919
[TBL] [Abstract][Full Text] [Related]
29. Propentophylline increases striatal dopamine release but dampens methamphetamine-induced dopamine dynamics: A microdialysis study.
Gough B; Pereira FC; Fontes Ribeiro CA; Ali SF; Binienda ZK
Neurochem Int; 2014 Oct; 76():109-13. PubMed ID: 25049173
[TBL] [Abstract][Full Text] [Related]
30. The effects of intranigral GABA and dynorphin A injections on striatal dopamine and GABA release: evidence that dopamine provides inhibitory regulation of striatal GABA neurons via D2 receptors.
Reid MS; O'Connor WT; Herrera-Marschitz M; Ungerstedt U
Brain Res; 1990 Jun; 519(1-2):255-60. PubMed ID: 1975763
[TBL] [Abstract][Full Text] [Related]
31. Cocaine selectively increases striatonigral dynorphin levels by a dopaminergic mechanism.
Sivam SP
J Pharmacol Exp Ther; 1989 Sep; 250(3):818-24. PubMed ID: 2476548
[TBL] [Abstract][Full Text] [Related]
32. Effects of haloperidol and clozapine on preprotachykinin-A messenger RNA, tachykinin tissue levels, release and neurokinin-1 receptors in the striato-nigral system.
Humpel C; Knaus GA; Auer B; Knaus HG; Haring C; Theodorsson E; Saria A
Synapse; 1990; 6(1):1-9. PubMed ID: 1697986
[TBL] [Abstract][Full Text] [Related]
33. Distinct responses of basal ganglia substance P systems to low and high doses of methamphetamine.
Hanson GR; Bush L; Keefe KA; Alburges ME
J Neurochem; 2002 Sep; 82(5):1171-8. PubMed ID: 12358764
[TBL] [Abstract][Full Text] [Related]
34. Distinct presynaptic control of dopamine release in striosomal- and matrix-enriched areas of the rat striatum by selective agonists of NK1, NK2, and NK3 tachykinin receptors.
Tremblay L; Kemel ML; Desban M; Gauchy C; Glowinski J
Proc Natl Acad Sci U S A; 1992 Dec; 89(23):11214-8. PubMed ID: 1280822
[TBL] [Abstract][Full Text] [Related]
35. 17β-Estradiol infusions into the dorsal striatum rapidly increase dorsal striatal dopamine release in vivo.
Shams WM; Sanio C; Quinlan MG; Brake WG
Neuroscience; 2016 Aug; 330():162-70. PubMed ID: 27256507
[TBL] [Abstract][Full Text] [Related]
36. Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes.
Jiang HK; McGinty JF; Hong JS
Brain Res; 1990 Jan; 507(1):57-64. PubMed ID: 1967976
[TBL] [Abstract][Full Text] [Related]
37. Up-regulation of neurotensin mRNA in the rat striatum after acute methamphetamine treatment.
Castel MN; Morino P; Dagerlind A; Hökfelt T
Eur J Neurosci; 1994 Apr; 6(4):646-56. PubMed ID: 7517773
[TBL] [Abstract][Full Text] [Related]
38. Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity.
Bourque M; Liu B; Dluzen DE; Di Paolo T
Biochem Pharmacol; 2007 Nov; 74(9):1413-23. PubMed ID: 17825264
[TBL] [Abstract][Full Text] [Related]
39. Effect of neonatal hypoxia-ischemia on nigro-striatal dopamine receptors and on striatal neuropeptide Y, dynorphin A and substance P concentrations in rats.
Johnson M; Hanson GR; Gibb JW; Adair J; Filloux F
Brain Res Dev Brain Res; 1994 Nov; 83(1):109-18. PubMed ID: 7535199
[TBL] [Abstract][Full Text] [Related]
40. Dopamine D1 receptor-stimulated release of acetylcholine in rat striatum is mediated indirectly by activation of striatal neurokinin1 receptors.
Anderson JJ; Kuo S; Chase TN; Engber TM
J Pharmacol Exp Ther; 1994 Jun; 269(3):1144-51. PubMed ID: 7912277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
